1367366-96-8Relevant academic research and scientific papers
Discovery of Potent and Selective A2A Antagonists with Efficacy in Animal Models of Parkinson's Disease and Depression
Basu, Sujay,Barawkar, Dinesh A.,Ramdas, Vidya,Naykodi, Minakshi,Shejul, Yogesh D.,Patel, Meena,Thorat, Sachin,Panmand, Anil,Kashinath,Bonagiri, Rajesh,Prasad, Vandna,Bhat, Ganesh,Quraishi, Azfar,Chaudhary, Sumit,Magdum, Amol,Meru, Ashwinkumar V.,Ghosh, Indraneel,Bhamidipati, Ravi K.,Raje, Amol A.,Madgula, Vamsi L. M.,De, Siddhartha,Rouduri, Sreekanth R.,Palle, Venkata P.,Chugh, Anita,Hariharan, Narayanan,Mookhtiar, Kasim A.
, p. 835 - 840 (2017/08/16)
Adenosine A2A receptor (A2AAdoR) antagonism is a nondopaminergic approach to Parkinson's disease treatment that is under development. Earlier we had reported the therapeutic potential of 7-methoxy-4-morpholino-benzothiazole derivativ
FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST
-
, (2012/04/10)
The present disclosure relates to fused tricyclic compounds of formula (I) or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating condit
